Immune cell levels may guide breast cancer treatment in new trial

NCT ID NCT05645380

Ongoing Disease control Sponsor: University of Kansas Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether the number of immune cells in and around a triple-negative breast cancer tumor can help doctors personalize chemotherapy and immunotherapy. About 139 women with early-stage triple-negative breast cancer will receive standard chemotherapy drugs plus pembrolizumab (Keytruda). The goal is to see if those with high immune cell levels and good early response can have better tumor shrinkage, potentially reducing the need for more aggressive treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Carboplatin, Docetaxel, Doxorubicin, Cyclophosphamide, Pembrolizumab
What this could lead to: If successful, this could lead to a more personalized treatment approach for triple-negative breast cancer, potentially improving tumor shrinkage and reducing unnecessary chemotherapy.
What could go wrong: This is a phase 2 trial with 139 participants, so results are preliminary. The approach may not work for all patients, and chemotherapy drugs have significant side effects like fatigue, nausea, and increased infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

The University of Kansas Cancer Center - Clinical Research Center

Fairway, Kansas, 66205, United States
The University of Kansas Cancer Center - Lee's Summit

Lee's Summit, Missouri, 64064, United States
The University of Kansas Cancer Center - Main Hospital

Kansas City, Kansas, 66160, United States
The University of Kansas Cancer Center - North

Kansas City, Missouri, 64154, United States
The University of Kansas Cancer Center - Overland Park

Overland Park, Kansas, 66210, United States
The University of Kansas Cancer Center - Westwood

Kansas City, Kansas, 66205, United States
University of Kansas Cancer Center at North Kansas City Hospital

North Kansas City, Missouri, 64116, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.